- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05172726
소아 환자의 판상 건선 치료를 위한 Tapinarof
소아 피험자의 판상 건선 치료를 위한 Tapinarof의 3상 연구
This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.
연구 개요
상세 설명
This study is an open-label study, consisting of a 12-week primary treatment phase and an optional 40-week long-term extension phase in which all eligible subjects will receive tapinarof cream, 1% once daily. At the end of the 12-week primary treatment phase subjects will have the option to continue for 40 additional weeks of treatment. Subjects who choose not to participate in the optional 40-week long-term extension phase will complete a follow-up visit approximately one week after the end of the primary treatment phase.
연구 유형
등록 (실제)
단계
- 3단계
연락처 및 위치
연구 장소
-
-
Arkansas
-
Rogers, Arkansas, 미국, 72758
- Northwest Arkansas Clinical Trials Center, PLLC
-
-
California
-
Fountain Valley, California, 미국, 92708
- First OC Dermatology
-
Rancho Santa Margarita, California, 미국, 92688
- Mission Dermatology Center
-
-
Florida
-
Miami Lakes, Florida, 미국, 33014
- San Marcus Research Clinic, Inc.
-
Miami Lakes, Florida, 미국, 33014
- RM Medical Research
-
Tampa, Florida, 미국, 33615
- Olympian Clinical Research
-
-
Illinois
-
Chicago, Illinois, 미국, 60611
- Northwestern University Feinberg School of Medicine
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46250
- Dawes Fretzin Clinical Research Group
-
West Lafayette, Indiana, 미국, 47906
- Options Research Group
-
-
Ohio
-
Fairborn, Ohio, 미국, 45324
- Wright State Physicians Pharmacology Translational Unit
-
-
Oregon
-
Portland, Oregon, 미국, 97210
- Oregon Dermatology & Research Center
-
-
Washington
-
Spokane, Washington, 미국, 99202
- Dermatology Specialists of Spokane
-
-
-
-
Alberta
-
Calgary, Alberta, 캐나다, T2J7E1
- Dermatology Research Institute Inc.
-
Edmonton, Alberta, 캐나다, T5J3S9
- Rejuvenation Laser Dermatology Clinics
-
-
Newfoundland and Labrador
-
St. John's, Newfoundland and Labrador, 캐나다, A1E1V4
- Skincare Studio INC
-
-
Ontario
-
Markham, Ontario, 캐나다, L3P1X3
- Lynderm Research Inc.
-
Waterloo, Ontario, 캐나다, N2J 1C4
- Alliance Clinical Trials
-
Whitby, Ontario, 캐나다, L1P0P9
- Whitby Health Centre Dermatology Trials
-
-
Quebec
-
Montreal, Quebec, 캐나다, H2X 2V1
- Innovaderm Research, Inc.
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male and female subjects ages 2 to 17 years with clinical diagnosis of chronic plaque psoriasis and stable disease for at least 3 months prior to the baseline visit
- Subject with plaque psoriasis covering ≥ 3% of the BSA at screening and baseline
- A PGA score of ≥ 2 at screening and baseline
- Female subjects of childbearing potential who are engaging in sexual activity that could lead to pregnancy should use acceptable birth control methods
- Must not be pregnant
- Subject, subject's parent, or legal representative must be capable of giving written informed consent/assent
Exclusion Criteria:
- Psoriasis other than plaque variant
- Any sign of infection of any of the psoriatic lesions
- Immunocompromised at screening
- Screening alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥2.0x the upper limit of normal (ULN)
- Screening total bilirubin > 1.5x ULN
- Current or chronic history of liver disease
- Current or history of cancer within 5 years except for adequately treated cutaneous basal cell carcinoma, squamous cell carcinoma or carcinoma in situ of the cervix
- Major surgery within 8 weeks prior to baseline or has a major surgery planned during the study
- Known history of clinically significant drug or alcohol abuse in the last year prior to baseline
- Use of any prohibited medication or procedure within the indicated period before the baseline visit until the completion of the study completion or study discontinuation
- History of or ongoing serious illness or medical, physical, or psychiatric condition(s) that, in the Investigator's opinion may interfere with the subject's participation in the study, interpretation of results, safety of the subject or ability to understand and give informed consent
- Pregnant or lactating females.
- History of sensitivity to the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator or Medical Monitor, contraindicates their participation
- Previous known participation in a clinical study with tapinarof (previously known as GSK2894512 and WBI-1001)
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: 오픈 라벨
|
applied topically once daily |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
임상적으로 유의미한 검사실 검사 이상이 있는 피험자 수
기간: 53주차까지 스크리닝
|
53주차까지 스크리닝
|
|
|
임상적으로 유의미한 활력징후 이상이 있는 피험자 수
기간: 53주차까지 스크리닝
|
53주차까지 스크리닝
|
|
|
Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: Screening up to Week 53
|
Incidence, frequency, and duration of treatment emergent AEs and SAEs |
Screening up to Week 53
|
|
Investigator-Assessed Local Tolerability Scale (LTS) Scores
기간: Baseline up to Week 52
|
Local Tolerability Scale (LTS) is a clinical tool for assessing the presence and overall degree of irritation at the application sites, according to a 5-point scale (0-4). Higher LTS scores represent more severe irritation. |
Baseline up to Week 52
|
|
Subject (or Caregiver)-Assessed Local Tolerability Scale (LTS)
기간: Baseline up to Week 52
|
Local Tolerability Scale (LTS) is a clinical tool for assessing the presence and overall degree of irritation at the application sites, according to a 5-point scale (0-4). Higher LTS scores represent more severe irritation. |
Baseline up to Week 52
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Detectable Time-Point (AUC0-t) of tapinarof cream, 1%.
기간: Week 4 and Week 12
|
Area under the plasma concentration-time curve from time zero to the last quantifiable time point. |
Week 4 and Week 12
|
|
Maximum Plasma Concentration (Cmax) of tapinarof cream, 1%.
기간: Week 4 and Week 12
|
Maximum observed plasma concentration (Cmax). |
Week 4 and Week 12
|
|
Time to Maximum Plasma Concentration (tmax) of tapinarof cream, 1%.
기간: Week 4 and Week 12
|
Time to maximum observed plasma concentration obtained directly from the observed concentration. |
Week 4 and Week 12
|
공동 작업자 및 조사자
스폰서
수사관
- 연구 책임자: Clinical Lead Late-Stage Clinical Development, Organon and Co
간행물 및 유용한 링크
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .